Trexquant Investment LP Has $4.94 Million Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Trexquant Investment LP grew its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 867.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 566,945 shares of the company’s stock after purchasing an additional 508,362 shares during the quarter. Trexquant Investment LP’s holdings in Kura Oncology were worth $4,938,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KURA. Vanguard Group Inc. grew its stake in shares of Kura Oncology by 14.6% during the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock worth $41,973,000 after purchasing an additional 615,211 shares during the period. Harbor Advisors LLC acquired a new position in shares of Kura Oncology during the 4th quarter worth about $87,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Kura Oncology in the 4th quarter valued at approximately $127,000. Sei Investments Co. boosted its stake in Kura Oncology by 41.0% during the 4th quarter. Sei Investments Co. now owns 20,815 shares of the company’s stock worth $181,000 after acquiring an additional 6,055 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in Kura Oncology by 101.6% during the fourth quarter. American Century Companies Inc. now owns 66,706 shares of the company’s stock valued at $581,000 after purchasing an additional 33,612 shares during the period.

Wall Street Analyst Weigh In

KURA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. Scotiabank lowered their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Kura Oncology Stock Down 4.5 %

Shares of Kura Oncology stock opened at $5.89 on Friday. Kura Oncology, Inc. has a 52-week low of $5.82 and a 52-week high of $23.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The business’s 50 day simple moving average is $7.68 and its 200 day simple moving average is $11.51. The firm has a market cap of $475.65 million, a PE ratio of -2.50 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.